Hikal Q1 FY27 Earnings Call Scheduled for August 6 at 5 PM IST
Hikal Limited has scheduled a Q1FY27 earnings conference call for August 6, 2026, at 5:00 PM IST, facilitated by Strategic Growth Advisors Pvt. Ltd. Senior leadership, including Vice Chairman and MD Sameer Hiremath and CFO Kuldeep Jain, will participate to discuss the company's financial and operational performance for the quarter ended June 30, 2026. Dial-in access is available across multiple regions including India, Hong Kong, Singapore, the UK, and the USA.
*this image is generated using AI for illustrative purposes only.
Hikal Limited will host an earnings group conference call on Thursday, August 06, 2026, at 5:00 PM IST to discuss its financial and operational performance for the quarter ended June 30, 2026. The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, providing investors with a direct channel to management for insights into Q1FY27 results. The company notified both the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the event. The intimation dated July 30, 2026, was signed by Company Secretary Rajasekhar Reddy Chintakindi, ensuring compliance with regulatory disclosure norms.
Conference Call Participants
Senior leadership from Hikal Limited will participate in the discussion to provide detailed commentary on the quarter's performance. The key participants are as follows:
| Name: | Designation |
|---|---|
| Sameer Hiremath | Vice Chairman and Managing Director |
| Anish Swadi | Senior President, Business Transformation and Animal Health |
| Kuldeep Jain | Chief Financial Officer |
| Manoj Mehrotra | President, Pharmaceuticals Business |
Dial-In Details
Investors and analysts can join the call using the provided dial-in numbers. Strategic Growth Advisors Pvt. Ltd. is facilitating the registration process.
| Region: | Dial-In Number |
|---|---|
| Universal Access | +91 22 6280 1309, +91 22 7115 8210 |
| Hong Kong | 800964448 |
| Singapore | 8001012045 |
| UK | 08081011573 |
| USA | 18667462133 |
For RSVP inquiries, investors may contact Mr. Jigar Kavaiya at jigar.kavaiya@sgapl.net or Ms. Ami Parekh at ami.parekh@sgapl.net .
What This Means for Investors
The conference call serves as a critical platform for stakeholders to understand the drivers behind Hikal Limited's Q1FY27 financial results. With participation from the CFO and business heads, the session is expected to cover segment-wise performance, particularly in Pharmaceuticals and Animal Health, as well as broader business transformation initiatives. Investors should note that no specific financial figures were disclosed in this announcement; all material data will be presented during the live discussion.
Historical Stock Returns for Hikal
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.68% | -2.75% | -5.67% | +4.11% | -16.41% | -63.72% |
How will Hikal's Q1FY27 performance in the Animal Health segment influence its long-term growth strategy amidst evolving global veterinary market trends?
What specific milestones in the business transformation initiatives led by Anish Swadi are expected to drive operational efficiency improvements in subsequent quarters?
Given the participation of the Pharmaceuticals Business President, will there be any updates on the pipeline status or regulatory approvals for key generic drug candidates?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
